Parabiotic is developing combination antibiotic/probiotic drugs for the treatment of Inflammatory Bowel disease while minimizing the side effects of antibiotics
Parabiotic R&D is virtual company focused on the development of innovative combination antibiotic/probiotic drug products for the treatment of Inflammatory Bowel and Infectious diseases. The company has three patent applications on file for products PB1, PB-2, PB-3. Our intention is to develop the lead product PB-1 through Phase II clinical studies and then partner/license the products to a Pharma partner who has a presence in GI. drugs.